Recursion Pharmaceuticals Valuation
| RXRX Stock | USD 7.01 0.34 5.10% |
At this time, the company appears to be undervalued. Recursion Pharmaceuticals holds a recent Real Value of $9.29 per share. The prevailing price of the company is $7.01. Our model determines the value of Recursion Pharmaceuticals from analyzing the company fundamentals such as Shares Owned By Insiders of 4.44 %, return on equity of -0.71, and Current Valuation of 1.56 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Recursion Pharmaceuticals' valuation include:
Price Book 3.3271 | Enterprise Value 1.6 B | Enterprise Value Ebitda (5.31) | Price Sales 41.1728 | Enterprise Value Revenue 32.0855 |
Undervalued
Today
Please note that Recursion Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Recursion Pharmaceuticals is based on 3 months time horizon. Increasing Recursion Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Recursion Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Recursion Stock. However, Recursion Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.01 | Real 9.29 | Target 16.83 | Hype 7.01 | Naive 7.01 |
The intrinsic value of Recursion Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Recursion Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Recursion Pharmaceuticals helps investors to forecast how Recursion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Recursion Pharmaceuticals more accurately as focusing exclusively on Recursion Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Recursion Pharmaceuticals' intrinsic value based on its ongoing forecasts of Recursion Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Recursion Pharmaceuticals' closest peers.
Recursion Pharmaceuticals Cash |
|
Recursion Valuation Trend
Analysing the historical paterns of Recursion Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Recursion Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Recursion Revenue by Product
Recursion Pharmaceuticals Total Value Analysis
Recursion Pharmaceuticals is at this time projected to have valuation of 1.56 B with market capitalization of 2.04 B, debt of 50.67 M, and cash on hands of 515.44 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Recursion Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.56 B | 2.04 B | 50.67 M | 515.44 M |
Recursion Pharmaceuticals Investor Information
About 89.0% of the company shares are owned by institutional investors. The book value of Recursion Pharmaceuticals was at this time reported as 2.08. The company recorded a loss per share of 1.74. Recursion Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Recursion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Recursion Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in November.Recursion Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Recursion Pharmaceuticals has an asset utilization ratio of 6.82 percent. This suggests that the Company is making $0.0682 for each dollar of assets. An increasing asset utilization means that Recursion Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Recursion Pharmaceuticals Ownership Allocation
Recursion Pharmaceuticals owns a total of 284.19 Million outstanding shares. The majority of Recursion Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Recursion Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Recursion Pharmaceuticals. Please pay attention to any change in the institutional holdings of Recursion Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Recursion Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 44.58 M. Net Loss for the year was (328.07 M) with loss before overhead, payroll, taxes, and interest of (164.13 M).About Recursion Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Recursion Pharmaceuticals. We calculate exposure to Recursion Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Recursion Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -6.5 M | -6.8 M | |
| Pretax Profit Margin | (7.45) | (7.82) | |
| Operating Profit Margin | (7.85) | (8.25) | |
| Net Loss | (7.36) | (7.73) | |
| Gross Profit Margin | (0.15) | (0.15) |
Recursion Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 207.9 M |
Recursion Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Recursion Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Recursion we look at many different elements of the entity such as Recursion's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Recursion Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Recursion Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Recursion Pharmaceuticals' worth.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.